372 related articles for article (PubMed ID: 11502811)
1. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.
Hooft L; Hoekstra OS; Devillé W; Lips P; Teule GJ; Boers M; van Tulder MW
J Clin Endocrinol Metab; 2001 Aug; 86(8):3779-86. PubMed ID: 11502811
[TBL] [Abstract][Full Text] [Related]
2. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
3. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: A meta-analysis.
Caetano R; Bastos CR; de Oliveira IA; da Silva RM; Fortes CP; Pepe VL; Reis LG; Braga JU
Head Neck; 2016 Feb; 38(2):316-27. PubMed ID: 25251544
[TBL] [Abstract][Full Text] [Related]
5. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
[TBL] [Abstract][Full Text] [Related]
6. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
7. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
Gutiérrez Cardo AL; Rodríguez Rodríguez JR; Borrego Dorado I; Navarro González E; Tirado Hospital JL; Vázquez Albertino R
Rev Esp Med Nucl; 2007; 26(3):138-45. PubMed ID: 17524307
[TBL] [Abstract][Full Text] [Related]
8. The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma.
Goshen E; Cohen O; Rotenberg G; Oksman Y; Karasik A; Zwas ST
Nucl Med Commun; 2003 Sep; 24(9):959-61. PubMed ID: 12960594
[TBL] [Abstract][Full Text] [Related]
9. [Value of F-18 fluorodeoxyglucose positron emission tomography in thyroid carcinoma].
Kumnig G
Wien Med Wochenschr; 2002; 152(11-12):280-5. PubMed ID: 12138656
[TBL] [Abstract][Full Text] [Related]
10. Early recurrence of papillary and follicular thyroid carcinoma predicts a worse outcome.
Lin JD; Hsueh C; Chao TC
Thyroid; 2009 Oct; 19(10):1053-9. PubMed ID: 19772423
[TBL] [Abstract][Full Text] [Related]
11. [Utility of positron emission tomography with fluorodeoxyglucose (FDG-PET) in the evaluation of thyroid cancer: a systematic review].
Kuba VM; Caetano R; Coeli CM; Vaisman M
Arq Bras Endocrinol Metabol; 2007 Aug; 51(6):961-71. PubMed ID: 17934664
[TBL] [Abstract][Full Text] [Related]
12. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
Ong SC; Ng DC; Sundram FX
Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
[TBL] [Abstract][Full Text] [Related]
13. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review.
Miller ME; Chen Q; Elashoff D; Abemayor E; St John M
Head Neck; 2011 Apr; 33(4):562-5. PubMed ID: 20665734
[TBL] [Abstract][Full Text] [Related]
15. [18F]fluorodeoxyglucose triple-head coincidence imaging as an adjunct to 131I scanning for follow-up of papillary thyroid carcinoma.
Gonzalo IT; Itti E; Mlikotic A; Pham le H; Cesar RB; Meignan M; Mishkin FS
Endocr Pract; 2003; 9(4):273-9. PubMed ID: 14561570
[TBL] [Abstract][Full Text] [Related]
16. Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
Moog F; Linke R; Manthey N; Tiling R; Knesewitsch P; Tatsch K; Hahn K
J Nucl Med; 2000 Dec; 41(12):1989-95. PubMed ID: 11138683
[TBL] [Abstract][Full Text] [Related]
17. Correlation of BRAF mutation and SUV
Ozderya A; Temizkan S; Gul AE; Ozugur S; Sargin M; Aydin K
Endocrine; 2017 Jan; 55(1):215-222. PubMed ID: 27696232
[TBL] [Abstract][Full Text] [Related]
18. Detection of papillary thyroid cancer brain metastasis with FDG-PET/CT.
Rini JN; Nguyen VT; Ben-Levi E; Naidich JJ; Yi Li J; Palestro CJ
Clin Nucl Med; 2010 May; 35(5):357-9. PubMed ID: 20395715
[No Abstract] [Full Text] [Related]
19. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients.
Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW
J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003
[TBL] [Abstract][Full Text] [Related]
20. Is there a role for sandostatin treatment in patients with progressive thyroid cancer and iodine-negative but somatostatin-receptor-positive metastases?
Kohlfuerst S; Igerc I; Gallowitsch HJ; Gomez I; Kresnik E; Matschnig S; Lind P
Thyroid; 2006 Nov; 16(11):1113-9. PubMed ID: 17123338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
